The world bio-informatics market is at $1.4 billion and is expected to grow at an annual average growth rate of 15.8% to reach about $3 billion by 2010, with focus on Chem-informatics and Pharmaco-gen
December 6, 2005 (Press Release) --
The world bio-informatics market is at $1.4 billion and is expected to grow at an annual average growth rate of 15.8% to reach about $3 billion by 2010, with focus on Chem-informatics and Pharmaco-genomics.
RNCOS' market research report namely "World Bio-Informatics Market (2005-2010)" has estimated that the top 20 bio-informatics companies have doubled their R&D expenditure from $40 billion in 2000 to $80 billion in 2005. This increased expenditure is due to the highly stimulated demand to come up with new molecules. Revenues would grow by 7% per annum for the next five years. R&D outsourced was about 40% of R&D expenses in 2004. Drug Majors sourced approximately 25% of R&D.
Bio-informatics has comparative advantage in facilitating creation and commercialization of agricultural, industrial, pharmaceutical and environmental products. It can reduce drug discovery and development costs.
The larger bio-informatics units shall be forced to reduce their R&D costs and encourage R&D initiatives with smaller bio-tech companies through collaborations and contracts. Presently the major industries are interested in a consolidation track forcing small firms to find ways to remain autonomous. Competition in some market segments are expected to be restricted as large scale acquisitions and mergers continue.
To purchase your copy: http://www.marketsmonitor.com/category/Biotech13.html
For more information about the report please visit www.marketsmonitor.com
RNCOS' market research report namely "World Bio-Informatics Market (2005-2010)" has estimated that the top 20 bio-informatics companies have doubled their R&D expenditure from $40 billion in 2000 to $80 billion in 2005. This increased expenditure is due to the highly stimulated demand to come up with new molecules. Revenues would grow by 7% per annum for the next five years. R&D outsourced was about 40% of R&D expenses in 2004. Drug Majors sourced approximately 25% of R&D.
Bio-informatics has comparative advantage in facilitating creation and commercialization of agricultural, industrial, pharmaceutical and environmental products. It can reduce drug discovery and development costs.
The larger bio-informatics units shall be forced to reduce their R&D costs and encourage R&D initiatives with smaller bio-tech companies through collaborations and contracts. Presently the major industries are interested in a consolidation track forcing small firms to find ways to remain autonomous. Competition in some market segments are expected to be restricted as large scale acquisitions and mergers continue.
To purchase your copy: http://www.marketsmonitor.com/category/Biotech13.html
For more information about the report please visit www.marketsmonitor.com
Email
Print
SPAM
